CL2014003531A1 - Suministro de farmaco diodegradable para las composiciones hidrofóbicas y su metodo de preparacion. - Google Patents

Suministro de farmaco diodegradable para las composiciones hidrofóbicas y su metodo de preparacion.

Info

Publication number
CL2014003531A1
CL2014003531A1 CL2014003531A CL2014003531A CL2014003531A1 CL 2014003531 A1 CL2014003531 A1 CL 2014003531A1 CL 2014003531 A CL2014003531 A CL 2014003531A CL 2014003531 A CL2014003531 A CL 2014003531A CL 2014003531 A1 CL2014003531 A1 CL 2014003531A1
Authority
CL
Chile
Prior art keywords
diodegradable
preparation
drug supply
hydrophobic compositions
hydrophobic
Prior art date
Application number
CL2014003531A
Other languages
English (en)
Spanish (es)
Inventor
Georges Gaudriault
Christophe Roberge
Original Assignee
Medincell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49117888&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003531(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medincell filed Critical Medincell
Publication of CL2014003531A1 publication Critical patent/CL2014003531A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2014003531A 2012-06-27 2014-12-24 Suministro de farmaco diodegradable para las composiciones hidrofóbicas y su metodo de preparacion. CL2014003531A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261665192P 2012-06-27 2012-06-27

Publications (1)

Publication Number Publication Date
CL2014003531A1 true CL2014003531A1 (es) 2015-08-28

Family

ID=49117888

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003531A CL2014003531A1 (es) 2012-06-27 2014-12-24 Suministro de farmaco diodegradable para las composiciones hidrofóbicas y su metodo de preparacion.

Country Status (23)

Country Link
US (5) US20150150987A1 (enExample)
EP (1) EP2866837B1 (enExample)
JP (1) JP6134788B2 (enExample)
KR (1) KR102189442B1 (enExample)
CN (1) CN104582733B (enExample)
AU (1) AU2013282891B2 (enExample)
BR (1) BR112014031773B1 (enExample)
CA (1) CA2877083C (enExample)
CL (1) CL2014003531A1 (enExample)
CO (1) CO7160098A2 (enExample)
CR (1) CR20140581A (enExample)
CU (1) CU24287B1 (enExample)
EA (1) EA031522B1 (enExample)
ES (1) ES2938586T3 (enExample)
IL (1) IL236472B (enExample)
IN (1) IN2014DN11063A (enExample)
MA (1) MA37809B1 (enExample)
MX (1) MX353280B (enExample)
SG (1) SG11201408658PA (enExample)
TN (1) TN2014000520A1 (enExample)
UA (1) UA113549C2 (enExample)
WO (2) WO2014001905A1 (enExample)
ZA (1) ZA201409291B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
UA119324C2 (uk) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10251937B2 (en) 2014-01-27 2019-04-09 Medincell Retro-inverso analogs of spadin display increased antidepressant effects
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20170290846A1 (en) * 2014-09-30 2017-10-12 University Of Tennessee Research Foundation In situ gelling form for long-acting drug delivery
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
FR3027522B1 (fr) 2014-10-27 2016-12-09 I Ceram Composition poreuse chargee en principe actif
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
FI3377041T3 (fi) * 2015-11-16 2023-11-30 Medincell S A Menetelmä farmaseuttisesti aktiivisten pääainesosien morselloimiseksi ja/tai kohdentamiseksi synoviaalikudokseen
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US11766400B2 (en) * 2016-10-24 2023-09-26 Yale University Biodegradable contraceptive implants
CA3057438A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
US11666527B2 (en) * 2017-07-17 2023-06-06 Medincell Biodegradable block copolymer drug delivery composition
GB2568526A (en) 2017-11-20 2019-05-22 Rebio Tech Oy Composition
CN108078911A (zh) * 2017-12-08 2018-05-29 复旦大学 用于动物避孕的热致水凝胶缓释兽药注射剂及其制备方法
ES2990218T3 (es) * 2018-08-22 2024-11-29 Bacainn Biotherapeutics Ltd Composiciones de ciclosporina y métodos de uso
GB201900258D0 (en) 2019-01-08 2019-02-27 Medincell Pharmaceutical composition
BR112022004535A2 (pt) * 2019-09-13 2022-06-07 Medincell S A Formulações de entrega de fármaco
CN111700876A (zh) * 2020-03-12 2020-09-25 上海市肿瘤研究所 一种治疗系统性红斑狼疮的载药递送给药系统及其制备方法
EP4262749A1 (en) 2020-12-16 2023-10-25 Medincell S.A. Methods and compositions for the prophylactic treatment of sars-cov-2 virus (covid-19)
FI20215186A1 (en) 2021-02-19 2022-08-20 Rebio Tech Oy Compositions for ophthalmic treatment
MX2023010925A (es) 2021-03-17 2023-09-27 Medincell S A Formulacion inyectable de accion prolongada que comprende risperidona y polimeros biodegradables.
US20240325294A1 (en) * 2021-04-30 2024-10-03 Medincell Sa Etonogestrel formulation
WO2025081046A1 (en) * 2023-10-11 2025-04-17 The Brigham And Women's Hospital, Inc. Ultra-high drug loading injectable drug suspension of hydrophobic drugs for long-term drug delivery

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
HU222501B1 (hu) * 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
KR0180334B1 (ko) * 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
FR2741628B1 (fr) 1995-11-29 1998-02-06 Centre Nat Rech Scient Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
DK1343530T3 (da) * 2000-11-09 2007-10-15 Astrazeneca Ab Oral farmaceutisk sammensætning, der indeholder en blokcopolymer
KR100446101B1 (ko) * 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
DK1392254T3 (da) 2001-04-20 2007-07-02 Univ British Columbia Micelle-lægemiddelindgivelsessystem for hydrofobe lægemidler
US6592899B2 (en) 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
PT1638535E (pt) * 2003-06-26 2007-11-08 Mediolanum Pharmaceuticals Ltd Implantes subcutâneos com libertação inicial de princípio activo limitada e subsequente sua libertação extensiva com variação linear
US20050112170A1 (en) 2003-11-20 2005-05-26 Hossainy Syed F. Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same
AU2006278328A1 (en) * 2005-08-04 2007-02-15 Angiotech International Ag Block copolymer compositions and uses thereof
CN101273963A (zh) * 2007-11-22 2008-10-01 山东蓝金生物工程有限公司 一种含激素类抗癌药的温控缓释注射剂
US8846068B2 (en) * 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
JP5449388B2 (ja) * 2008-11-21 2014-03-19 サミャン バイオファーマシューティカルズ コーポレイション 耐性がん治療用高分子ミセル組成物及びその製造方法
CN101810560B (zh) * 2009-02-20 2013-07-10 北京大学 环孢a聚合物胶束组合物
SG10201508568VA (en) * 2010-12-29 2015-11-27 Medincell Biodegradable drug delivery compositions

Also Published As

Publication number Publication date
CO7160098A2 (es) 2015-01-15
MX2014015902A (es) 2015-07-17
JP6134788B2 (ja) 2017-05-24
BR112014031773A2 (pt) 2017-06-27
UA113549C2 (xx) 2017-02-10
MA37809B1 (fr) 2018-12-31
CR20140581A (es) 2015-02-06
KR20150027265A (ko) 2015-03-11
MA37809A1 (fr) 2017-07-31
US20210008216A1 (en) 2021-01-14
WO2014001904A1 (en) 2014-01-03
SG11201408658PA (en) 2015-02-27
JP2015522001A (ja) 2015-08-03
CU24287B1 (es) 2017-12-08
WO2014001905A1 (en) 2014-01-03
BR112014031773B1 (pt) 2020-10-13
CA2877083C (en) 2020-10-06
HK1208374A1 (en) 2016-03-04
IN2014DN11063A (enExample) 2015-09-25
US20150150987A1 (en) 2015-06-04
MX353280B (es) 2018-01-05
KR102189442B1 (ko) 2020-12-11
TN2014000520A1 (en) 2016-03-30
EA201492172A1 (ru) 2015-09-30
IL236472A0 (en) 2015-02-26
US20200085958A1 (en) 2020-03-19
AU2013282891A2 (en) 2015-02-05
AU2013282891B2 (en) 2018-04-12
EA031522B1 (ru) 2019-01-31
CN104582733A (zh) 2015-04-29
US20220354956A1 (en) 2022-11-10
IL236472B (en) 2020-02-27
EP2866837A1 (en) 2015-05-06
CN104582733B (zh) 2017-07-04
CA2877083A1 (en) 2014-01-02
US20190160171A1 (en) 2019-05-30
AU2013282891A1 (en) 2015-01-22
ES2938586T3 (es) 2023-04-12
ZA201409291B (en) 2017-05-31
CU20140148A7 (es) 2015-03-30
EP2866837B1 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
CL2014003531A1 (es) Suministro de farmaco diodegradable para las composiciones hidrofóbicas y su metodo de preparacion.
CO6880066A2 (es) Composición farmacéutica de sabor enmascarado
BR112013030472A2 (pt) formulação farmacêutica, artigo de fabricação e método
CO7061081A2 (es) Derivados macrocíclicos para el tratamiento de enfermedades
DK3068392T3 (da) Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme
PT3030262T (pt) Composição farmacêutica de associação
PL3424955T3 (pl) Metoda wytwarzania koniugatu przeciwciało-lek anty-trop2
HUE036887T2 (hu) Eljárás epesav-származékok elõállítására
CO6811868A2 (es) Combinaciones de principios activos
HRP20190332T1 (hr) Fungicidni pripravak i postupak za kontroliranje bolesti biljaka
CO6930363A2 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
ME03465B (me) Farmaceutska kompozicija s-ketamin hidrohlorida
BR112014011423A2 (pt) método para polinização de uma ou mais plantas
CL2015002754A1 (es) Método para descelularización de injertos de tejido
SG11201507347QA (en) Pharmaceutical composition of s-ketamine hydrochloride
PT2683708T (pt) Formas sólidas de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona, e suas composições e usos farmacêuticos
PT2854768T (pt) Composições farmacêuticas de pemetrexed
AR092198A1 (es) Derivados de pirazolopirimidinas
EP2925325A4 (en) STABILIZED FORMULATION OF PEMETREXED
BR112015002755A2 (pt) derivado de ácido hialurônico, método de preparação de derivado de ácido hialurônico, método de modificação de derivado de ácido hialurônico e uso de derivados
CO7091179A2 (es) Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
PT2859896T (pt) Composições farmacêuticas para o tratamento de distúrbios musculares
EP2919777A4 (en) TRANSMUCOSAL ADMINISTRATION OF TOCOTRIENOL
EP2990038A4 (en) SOLID PHARMACEUTICAL COMPOSITION
HRP20170171T1 (hr) Postupak za proizvodnju isavukonazola ili ravukonazola